Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)
Trial details
- Registry ID
- NCT07579910
- Drugs studied
- Tralesinidase alfa (TA)
TrialRedline tracks 7 clinical trials sponsored by Spruce Biosciences: 1 Phase 3, 6 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)NCT07579910 | Tralesinidase alfa (TA) | Not yet recruiting | 2033-08Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal HyperplasiaNCT03687242 | SPR001 | Completed | 2019-07-08Actual |
| Study of SPR001 in Adults With Classic Congenital Adrenal HyperplasiaNCT03257462 | SPR001 | Completed | 2019-03-02Actual |
| A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAHNCT05128942 | Tildacerfont | Terminated | 2025-01-31Actual |
| A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAHNCT04544410 | Not recorded | Terminated | 2024-10-31Actual |
| A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAHNCT04457336 | Not recorded | Terminated | 2024-02-09Actual |
| A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal AndrogensNCT05370521 | Tildacerfont | Terminated | 2023-08-03Actual |
Names as written in the registry records.